MURIANNI, VERONICA
 Distribuzione geografica
Continente #
EU - Europa 631
AS - Asia 124
NA - Nord America 54
SA - Sud America 17
AF - Africa 1
Totale 827
Nazione #
IT - Italia 610
SG - Singapore 57
US - Stati Uniti d'America 48
VN - Vietnam 33
CN - Cina 23
BR - Brasile 14
FR - Francia 9
CA - Canada 3
HK - Hong Kong 3
CO - Colombia 2
GB - Regno Unito 2
IN - India 2
MX - Messico 2
UA - Ucraina 2
AL - Albania 1
AT - Austria 1
CL - Cile 1
DE - Germania 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ES - Italia 1
FI - Finlandia 1
ID - Indonesia 1
IE - Irlanda 1
IQ - Iraq 1
JP - Giappone 1
NP - Nepal 1
SI - Slovenia 1
TH - Thailandia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 827
Città #
Genoa 422
Rapallo 74
Vado Ligure 66
Genova 44
Singapore 28
Ho Chi Minh City 12
Lauterbourg 8
San Jose 8
Council Bluffs 6
São Paulo 6
Ashburn 5
Beijing 5
Hanoi 3
Hong Kong 3
Orem 3
Biên Hòa 2
Haiphong 2
Kyiv 2
Los Angeles 2
Santa Clara 2
Atlanta 1
Basra 1
Bedsted Thy 1
Bilaspur 1
Bordighera 1
Brampton 1
Brooklyn 1
Bueno Brandão 1
Buffalo 1
Bình Phước 1
Canindé de São Francisco 1
Cardiff 1
Chennai 1
Da Nang 1
Dallas 1
Denver 1
Dublin 1
Elizabeth 1
Englewood 1
Frankfurt am Main 1
Fresno 1
Guadalupe 1
Guangzhou 1
Guarulhos 1
Helena 1
Huechuraba 1
Itapevi 1
Iztapalapa 1
Johannesburg 1
Kathmandu 1
Khon Kaen 1
Lappeenranta 1
Lauro de Freitas 1
Lavras 1
Ljubljana 1
London 1
Long Xuyen 1
Maceió 1
Madrid 1
Marseille 1
Montreal 1
New York 1
Nha Trang 1
Oklahoma City 1
Osasco 1
Pasto 1
Phủ Lý 1
Piscataway 1
Samarkand 1
Santa Marta 1
Santiago de los Caballeros 1
South Burlington 1
Thái Nguyên 1
Tirana 1
Toronto 1
Vienna 1
Vĩnh Lộc 1
Washington 1
Waterbury 1
Ân Thi 1
Totale 763
Nome #
802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study 147
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 116
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study) 105
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study 98
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) 98
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 89
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report 71
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 67
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) 60
Totale 851
Categoria #
all - tutte 3.705
article - articoli 3.705
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.410


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 2 7 4
2021/202227 0 0 3 2 0 0 0 6 5 1 3 7
2022/202387 5 6 0 11 13 7 5 11 9 4 15 1
2023/202494 4 5 3 8 4 23 3 2 4 7 5 26
2024/2025232 24 11 2 10 15 22 18 54 10 8 33 25
2025/2026389 58 46 38 39 42 19 34 15 56 42 0 0
Totale 851